论文部分内容阅读
Tykerb(lapatinib)已于2007年3月被FDA批准与罗氏公司的Xeoda(卡培他滨)联用,用于蒽环类抗生素、紫杉烷以及Herceptin无效的HER2阳性乳腺癌患者。约25%的乳腺癌HER2有过量表达。一项在580名HER2阴性或HER2基因状态未经检测的患者中进行的Ⅲ期临床研究表明,葛兰素史克公司的双重
Tykerb (lapatinib) was approved by the FDA in March 2007 for use with Roche’s Xeoda (capecitabine) for anthracyclines, taxanes, and Herceptin-null HER2-positive breast cancer patients. About 25% of breast cancer HER2 is overexpressed. A Phase III clinical study of 580 patients with no HER2-negative or HER2 gene status showed that GSK’s dual